Mitogen-Activated Protein Kinase Signal Transduction in Solid Tumors |
Lei, Yuan-Yuan
(Department of Pathology, the First Affiliated Hospital of Nanchang University)
Wang, Wei-Jia (Department of Pathology, the First Affiliated Hospital of Nanchang University) Mei, Jin-Hong (Department of Pathology, the First Affiliated Hospital of Nanchang University) Wang, Chun-Liang (Department of Neurosurgery, the First Affiliated Hospital of Nanchang University) |
1 | Ades F, Metzger-Filho O (2012). Targeting the cellular signaling: BRAF inhibition and beyond for the treatment of metastatic malignant melanoma. Dermatol Res Pract, 2012, 259170. |
2 | Ahmad I, Patel Y, Liu L. B, et al (2011). Ras mutation cooperates with beta-catenin activation to drive bladder tumourigenesis. Cell Death Dis, 2, 124. DOI |
3 | Bagley M, Davis P, Murziani S, et al (2010). Use of p38 MAPK inhibitors for the treatment of Werner Syndrome. Pharmaceuticals, 3, 1842-72. DOI |
4 | Ahn J, Eom C, Jeon S (2013). Acid suppressive drugs and gastric cancer: a meta-analysis of observational studies. World J Gastroenterol, 19, 2560-8. DOI |
5 | Amankwah E, Sellers T, Park Y (2012). Gene variants in the angiogenesis pathway and prostate cancer. Carcinogenesis, 33, 1259-69. DOI |
6 | Ara T, Declerck Y (2010). Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer, 46, 1223-31. DOI ScienceOn |
7 | Bauckman K, Haller E, Flores I, et al (2013). Iron modulates cell survival in a Ras- and MAPK-dependent manner in ovarian cells. Cell Death Dis, 4, 592. DOI |
8 | Bourboulia D, Stetler-Stevenson W (2010). Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol, 20, 161-8. DOI ScienceOn |
9 | Boyd F, Martin L, Bronskill M, et al (2010). Breast tissue composition and susceptibility to breast cancer. J Natl Cancer Inst, 102, 1224-37. DOI |
10 | Cargnello M, Roux P (2011). Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev, 75, 50-83. DOI ScienceOn |
11 | Cerne J, Stegel V, Gersak K, et al (2012). KRAS rs61764370 is associated with HER2-overexpressed and poorlydifferentiated breast cancer in hormone replacement therapy users: a case control study. BMC Cancer, 12, 105. DOI |
12 | Chang E, Yang J, Alfaro-Velcamp T, et al (2010). Disparities in liver cancer incidence by nativity, acculturation, and socioeconomic status in California Hispanics and Asians. Cancer Epidemiol Biomarkers Prev, 19, 3106-18. DOI |
13 | Clarke R, Schirra H, Catto J, et al (2010). Markers for detection of prostate cancer. Cancers, 2, 1125-54. DOI |
14 | Chao S, Huang S, et al (2013). Subtoxic Levels of Apigenin Inhibit Expression and Secretion of VEGF by Uveal Melanoma Cells via Suppression of ERK1/2 and PI3K/Akt Pathways. Evid Based Complement Alternat Med, 2013, 817674. |
15 | Charles N, Thomas P, Lange C (2010). Expression of membrane progesterone receptors (mPR/PAQR) in ovarian cancer cells: implications for progesterone-induced signaling events. Horm Cancer, 1, 167-76. DOI |
16 | Cheng Y, Ueno N (2012). Improvement of survival and prospect of cure in patients with metastatic breast cancer. Breast Cancer, 19, 191-9. DOI |
17 | Coleman R, Monk B, Sood A, et al (2013). Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol, 10, 211-4. DOI |
18 | Cust A, Armstrong B, Goumas C, et al (2011). Sunbed use during adolescence and early adulthood is associated with increased risk of early-onset melanoma. Int J Cancer, 128, 2425-35. DOI |
19 | Connolly R, Carducci M, et al (2012). Use of androgen deprivation therapy in prostate cancer: indications and prevalence. Asian J Androl, 14, 177-86. DOI |
20 | Curiel-Lewandrowski C, Chen C, Swetter S, et al (2012). Screening and prevention measures for melanoma: is there a survival advantage? Curr Oncol Rep, 14, 458-67. DOI |
21 | Davies M, Samuels Y (2010). Analysis of the genome to personalize therapy for melanoma. Oncogene, 29, 5545-55. DOI |
22 | Mello R, Marques D, Medeiros R, et al (2011). Epidermal growth factor receptor and K-Ras in non-small cell lung cancermolecular pathways involved and targeted therapies. World J Clin Oncol, 2, 367-76. DOI |
23 | Dey S, Ghosh N, Saha D, et al (2014). Matrix metalloproteinase-1 (MMP-1) Promoter polymorphisms are well linked with lower stomach tumor formation in eastern Indian population. PLoS One, 9, 88040. DOI |
24 | Dela Cruz C, Tanoue L, et al (2011). Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med, 32, 605-44. DOI |
25 | Demaria S, Pikarsky E, Karin M, et al (2010). Cancer and inflammation: promise for biologic therapy. J Immunother, 33, 335-51. DOI |
26 | Detchokul S, Frauman A (2011). Recent developments in prostate cancer biomarker research: therapeutic implications. Br J Clin Pharmacol, 71, 157-74. DOI |
27 | Dixon D, Blanco F, Bruno A, et al (2013). Mechanistic aspects of COX-2 expression in colorectal neoplasia. Rec Res Cancer Res, 91, 7-37. |
28 | Egleston B, Meireles S, Flieder D, et al (2009). Population-based trends in lung cancer incidence in women. Semin Oncol, 36, 506-15. DOI |
29 | Drake G (2010). Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol, 10, 580-93. DOI ScienceOn |
30 | Dudek A, Grotenhuis A, Vermeulen S, et al (2013). Urinary bladder cancer susceptibility markers. what do we know about functional mechanisms? Int J Mol Sci, 14, 12346-66. DOI ScienceOn |
31 | Evans M, Madhunapantula S, Robertson G, et al (2013). Current and future trials of targeted therapies in cutaneous melanoma. Adv Exp Med Biol, 779, 223-55. DOI |
32 | Falchook G, Lewis K, Infante J, et al (2012). Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncology, 13, 782-89. DOI ScienceOn |
33 | Galan-Moya E, Cruz-Morcillo M, Llanos Valero M, et al (2011). Balance between MKK6 and MKK3 mediates p38 MAPK associated resistance to cisplatin in NSCLC. PLoS One, 6, 28406. DOI |
34 | Grieco L, Calzone L, Bernard-Pierrot I, et al (2013). Integrative modelling of the influence of MAPK network on cancer cell fate decision. PLoS Comput Biol, 9, 1003286. DOI |
35 | Gholami S, Chen C, Gao S, Lou E, et al (2014). Role of MAPK in oncolytic herpes viral therapy in triple-negative breast cancer. Cancer Gene Ther, 21, 283-9. DOI |
36 | Gogoi R., Kudla M, Gil O, et al (2008). The activity of medroxyprogesterone acetate, an androgenic ligand, in ovarian cancer cell invasion. Reprod Sci, 15, 846-52. DOI |
37 | Inamdar G, Madhunapantula S, et al (2010). Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol, 80, 624-37. DOI |
38 | Gomes L, Terra L, Wailemann R, et al (2012). TGF-beta1 modulates the homeostasis between MMPs and MMP inhibitors through p38 MAPK and ERK1/2 in highly invasive breast cancer cells. BMC Cancer, 12, 26. DOI |
39 | Hassanein M, Callison J, Callaway-Lane C, et al (2012). The state of molecular biomarkers for the early detection of lung cancer. Cancer Prev Res, 5, 992-1006. DOI |
40 | Hollenhorst P, Ferris M, Hull M, et al (2011). Oncogenic ETS proteins mimic activated RAS/MAPK signaling in prostate cells. Genes Dev, 25, 2147-57. DOI |
41 | Izrailit J, Berman H, Datti K, et al (2013). High throughput kinase inhibitor screens reveal TRB3 and MAPK-ERK/TGFbeta pathways as fundamental Notch regulators in breast cancer. Proc Natl Acad Sci U S A, 110, 1714-9. DOI |
42 | Jeannin P, Duluc D, Delneste Y (2011). IL-6 and leukemiainhibitory factor are involved in the generation of tumorassociated macrophage: regulation by IFN-gamma. Immunotherapy, 3, 23-26. |
43 | Jelovac D, Armstrong D (2011). Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin, 61, 183-203. DOI |
44 | Kessenbrock K, Plaks V, Werb Z (2010). Matrix metalloproteinases: regulators of the tumor microenvironment. Cel, 141, 52-67. DOI ScienceOn |
45 | Jia-Qi S, Kun-Peng X, Wei Z (2014). Emodin inhibits breast cancer cell proliferation through the ER-MAPK/Akt-Cyclin D1/Bcl-2 signaling pathway. Asian Pac J Cancer Prev, 15, 6247-51. 과학기술학회마을 DOI |
46 | Koh C, Bieberich C, Dang C, et al (2010). MYC and prostate cancer. Genes Cancer, 1, 617-28. DOI |
47 | Jin J, Dayyani F, Gallick G (2011). Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer, 128, 2545-61. DOI |
48 | Kadara H, Kabbout M, Wistuba M (2012). Pulmonary adenocarcinoma: a renewed entity in 2011. Respirology, 17, 50-65. DOI ScienceOn |
49 | Khwaja F, Quann E, Pattabiraman N, et al (2008). Carprofen induction of p75NTR-dependent apoptosis via the p38 mitogen-activated protein kinase pathway in prostate cancer cells. Mol Cancer Ther, 7, 3539-45. DOI |
50 | Kohli M, Tindall D (2010). New developments in the medical management of prostate cancer. Mayo Clin Proc, 85, 77-86. DOI |
51 | Kompier L, Lurkin I, Aa M, et al (2010). FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One, 5, 13821. DOI ScienceOn |
52 | Korner A, Drapeau M, Thombs B, et al (2013). Barriers and facilitators of adherence to medical advice on skin selfexamination during melanoma follow-up care. BMC Dermatol, 13, 3. DOI |
53 | Koul H, Pal M, Koul S (2013). Role of p38 MAP Kinase Signal Transduction in Solid Tumors. Genes Cancer, 342-59. |
54 | Lamy E, Herz C, Lutz-Bonengel S, et al (2013). The MAPK pathway signals telomerase modulation in response to isothiocyanate-induced DNA damage of human liver cancer cells. PLoS One, 8, 53240. DOI |
55 | Li Y, Kong D, Bao B, et al (2011). Induction of cancer cell death by isoflavone: the role of multiple signaling pathways. Nutrients, 3, 877-96. DOI |
56 | Ligr M, Patwa R, Daniels G, et al (2011). Expression and function of androgen receptor coactivator p44/Mep50/WDR77 in ovarian cancer. PLoS One, 6, 26250. DOI |
57 | Larsen J, Cascone T, Gerber D, et al (2011). Targeted therapies for lung cancer: clinical experience and novel agents. Cancer J, 17, 512-27. DOI |
58 | Larsen J, Minna J (2011). Molecular biology of lung cancer: clinical implications. Clin Chest Med, 32, 703-40. DOI |
59 | Li C, Fan S, Owonikoko T, et al (2011). Oncogenic role of EAPII in lung cancer development and its activation of the MAPK-ERK pathway. Oncogene, 30, 3802-12. DOI |
60 | Lin K, Baritaki S, Militello L, et al (2010). The role of B-RAF mutations in melanoma and the induction of emt via dysregulation of the NF-kappaB/Snail/RKIP/PTEN circuit. Genes Cancer, 1, 409-20. DOI |
61 | Lin L, Deng W, Tian Y, et al (2014). Lasiodin inhibits proliferation of human nasopharyngeal carcinoma cells by simultaneous modulation of the Apaf-1/caspase, AKT/MAPK and COX-2/NF-kappaB signaling pathways. PLoS One, 9, 97799. DOI |
62 | Liu H, Wang L, Liu Z, et al (2013). Association between functional polymorphisms in genes involved in the MAPK signaling pathways and cutaneous melanoma risk. Carcinogenesis, 34, 885-92. DOI |
63 | Lofgren K, Ostrander J, et al (2011). Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK. Breast Cancer Res, 13, 89. DOI |
64 | Lv Z, Xu L (2012). Salvianolic Acid B Inhibits ERK and p38 MAPK Signaling in TGF-beta1-Stimulated Human Hepatic Stellate Cell Line (LX-2) via Distinct Pathways. Evid Based Complement Alternat Med, 2012, 960128. |
65 | Marshall A, Christiani D (2013). Genetic susceptibility to lung cancer--light at the end of the tunnel? Carcinogenesis, 34, 487-502. DOI |
66 | Matesic D, Sidorova T (2012). p38 MAPK activation, JNK inhibition, neoplastic growth inhibition, and increased gap junction communication in human lung carcinoma and Ras-transformed cells by 4-phenyl-3-butenoic acid. J Cell Biochem, 113, 269-81. DOI |
67 | Madhunapantula S, Robertson G (2012). Chemoprevention of melanoma. Adv Pharmacol, 65, 361-98. DOI |
68 | Mao L, Yuan L, Slakey L, et al (2010). Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway. Breast Cancer Res, 12107. |
69 | Mendoza M, Er E, et al (2010). ERK-MAP Kinase signaling in the cytoplasm. Methods Mol Biol, 661, 185-203. DOI |
70 | Merritt M, Cramer D (2010). Molecular pathogenesis of endometrial and ovarian cancer. Cancer Biomark, 9, 287-305. |
71 | Milone M, Pucci B, et al (2013). Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells. Cell Death Dis, 4, 641. DOI |
72 | Mimura K, Shiraishi K, Mueller A, et al (2013). The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer. J Immunol, 191, 6261-72. DOI |
73 | Mo L, Zheng X, Huang H, et al (2007). Hyperactivation of Haras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. J Clin Invest, 117, 314-25. DOI |
74 | Mohammad G, Mairaj Siddiquei M, Imtiaz Nawaz M, et al (2013). The ERK1/2 inhibitor U0126 attenuates diabetesinduced upregulation of MMP-9 and biomarkers of inflammation in the retina. J Diabetes Res, 2013, 658548. |
75 | Mo N, Li Z, Cao Y (2012). Curcumin inhibits TGF-1-induced MMP-9 and invasion through ERK and Smad signaling in breast cancer MDA-MB-231 Cells. Asian Pac J Cancer Prev, 13, 5709-14. 과학기술학회마을 DOI ScienceOn |
76 | Nagini S (2012). Carcinoma of the stomach: A review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol, 4, 156-69. DOI ScienceOn |
77 | Modugno F, Laskey R, Smith A, et al (2012). Hormone response in ovarian cancer: time to reconsider as a clinical target? Endocr Relat Cancer, 19, 255-79. DOI |
78 | Mulholland D, Kobayashi N, et al (2012). Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res, 72, 1878-89. DOI |
79 | Obata N, Tamakoshi K, et al (1997). Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma. Anticancer Res, 17, 337-42. |
80 | Ochoa C, Mirabolfathinejad S, et al (2011). Interleukin 6, but not T helper 2 cytokines, promotes lung carcinogenesis. Cancer Prev Res (Phila), 4, 51-64. DOI |
81 | Park M, Zhang G, et al (2008). Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95. Mol Cancer Ther, 7, 2633-48. DOI |
82 | Philbin M, Erby L, Lee S, et al (2012) Hepatitis B and liver cancer among three Asian American sub-groups: a focus group inquiry. J Immigr Minor Health, 14, 858-68. DOI |
83 | Park W, Amin A, Chen Z, et al (2013). New perspectives of curcumin in cancer prevention. Cancer Prev Res, 6, 387-400. DOI ScienceOn |
84 | Pereira L, Igea A, Canovas B, et al (2013). Inhibition of p38 MAPK sensitizes tumour cells to cisplatin-induced apoptosis mediated by reactive oxygen species and JNK. EMBO Mol Med, 5, 1759-74. DOI |
85 | Rountree C, Mishra L, et al (2012). Stem cells in liver diseases and cancer: recent advances on the path to new therapies. Hepatology, 55, 298-306. DOI |
86 | Polo M, Arnoni M, et al (2010). Responsiveness to PI3K and MEK inhibitors in breast cancer. Use of a 3D culture system to study pathways related to hormone independence in mice. PLoS One, 5, 10786. DOI |
87 | Rebecca V, Sondak V, et al (2012). A brief history of melanoma: from mummies to mutations. Melanoma Res, 22, 114-22. DOI |
88 | Saldanha S, Tollefsbol T (2014). Pathway modulations and epigenetic alterations in ovarian tumorbiogenesis. J Cell Physiol, 229, 393-406. DOI |
89 | Sfanos K, Marzo A (2012). Prostate cancer and inflammation: the evidence.Histopathology, 60, 199-215. DOI ScienceOn |
90 | Shen M, Abate-Shen C (2010). Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev, 24, 1967-2000. DOI |
91 | Shrestha Y, Schafer E, Boehm J, et al (2012). PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling. Oncogene, 31, 3397-408. DOI |
92 | Sukhtankar D, Okun A, Chandramouli A, et al (2011). Inhibition of p38-MAPK signaling pathway attenuates breast cancer induced bone pain and disease progression in a murine model of cancer-induced bone pain. Mol Pain, 7, 81. DOI |
93 | Slattery M, John E, et al (2013). Matrix metalloproteinase genes are associated with breast cancer risk and survival: the Breast Cancer Health Disparities Study. PLoS One, 8, 63165. DOI |
94 | Son T, Kwon I, Hyung W (2014). Minimally invasive surgery for gastric cancer treatment: current status and future perspectives. Gut Liver, 8, 229-36. DOI |
95 | Tsao H, Chin L, Garraway L, et al (2012). Melanoma: from mutations to medicine. Genes Dev, 26, 1131-55. DOI ScienceOn |
96 | Tanaka T, Miyazawa K, Tsukamoto T, et al (2011). Pathobiology and chemoprevention of bladder cancer. J Oncol, 2011, 528353. |
97 | Thanan R, Murata M, Ma N, et al (2012). Nuclear localization of COX-2 in relation to the expression of stemness markers in urinary bladder cancer. Mediators Inflamm, 2012, 165879. |
98 | Walia V, Mu W, Lin J, et al (2012). Delving into somatic variation in sporadic melanoma. Pigment Cell Melanoma Res, 25, 155-70. DOI |
99 | Wang C, Cigliano A, Delogu S, et al (2013). Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: implications for the treatment of human liver cancer. Cell Cycle, 12, 1999-2010. DOI |
100 | Wang J, Kobayashi T, Floc'h N, et al (2012). B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer. Cancer Res, 72, 4765-76. DOI |
101 | Westbrook K, Stearns V (2013). Pharmacogenomics of breast cancer therapy: an update. Pharmacol Ther, 139, 1-11. DOI |
102 | Zender L, Villanueva A, Tovar V, et al (2010). Cancer gene discovery in hepatocellular carcinoma. J Hepatol, 52, 921-9. DOI |
103 | Westin S, Herzog T, et al (2013). Investigational agents in development for the treatment of ovarian cancer. Invest New Drugs, 31, 213-29. DOI |
104 | Wilson K, Giovannucci E, et al (2012). Lifestyle and dietary factors in the prevention of lethal prostate cancer. Asian J Androl, 14, 365-74. DOI |
105 | Wu C, Zhu Z (2014). Diagnosis and evaluation of gastric cancer by positron emission tomography. World J Gastroenterol, 20, 4574-85. DOI |
106 | Wu H, Lin W, Tsai K (2014). Advances in molecular biomarkers for gastric cancer: miRNAs as emerging novel cancer markers. Expert Rev Mol Med, 16, 1. DOI |
107 | Xu Y, Li N, Xiang R, (2014). Emerging roles of the p38 MAPK and PI3K/AKT/mTOR pathways in oncogene-induced senescence. Trends Biochem Sci, 39, 268-76. DOI |
108 | Yang Y, Kim S, Yu T, et al (2014). Functional roles of p38 mitogen-activated protein kinase in macrophage-mediated inflammatory responses. Mediators Inflamm, 2014, 352371. |
109 | Zhang Z, Neiva K, Lingen M, et al (2010). VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell Death Differ, 17, 499-512. DOI ScienceOn |
110 | Liang-Rui Z, Xian C, Ke-Min W (2013). Radix tetrastigma Hemsleyani flavone induces apoptosis in human lung carcinoma A549 cells by modulating the MAPK pathway. Asian Pac J Cancer Prev, 14, 5983-87. 과학기술학회마을 DOI ScienceOn |